As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others
Diabetes-associated sustained activation of the transcription factor nuclear factor-B
It is the first membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), developed at the University of Texas in 2017
Se puede usar con otros pptidos
This information is not intended as medical advice